PharmaCyte Biotech Inc (PMCB)

[Kimori]

Very well said, jklm. I have posted once or twice before, but I read almost all the messages, and I always appreciate your positive comments. By the way, I have learned the other day that the drug for liver cancer that was made by Japanese pharmaceutical company, Eisai together with Merck, which FDA approved, is priced at $16,000 per month. The annual revenue they expect in 2022 is $3.2B. Again, they are just for liver cancer.
I was wondering how much PMCB will be worth when it will get bought out sometime next year.....